Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toludesvenlafaxine in somatic symptoms of depression
NCT05849272Phase 4Completed
- Sponsor
- Shanghai Mental Health Center
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toludesvenlafaxine in major depressive disorder (MDD), sponsored by Shanghai Mental Health Center. Primary endpoints: Patient Health Questionnaire-15 at 8 weeks and Somatic Symptom Scale - Chinese version at 8 weeks. Started May 2023; status: completed.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05849272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849272.